Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Ol'ga Yur'evna Vinogradova"'
Autor:
Anna Grigor'evna Turkina, Elena Vasil'evna Domracheva, Aleksandra Valer'evna Vorontsova, Elena Aleksandrovna Aseeva, Ol'ga Yur'evna Vinogradova, Ol'ga Veniaminovna Stakhina, Galina Anatol'evna Gusarova, Ol'ga Arkad'evna Dyagileva, Elena Aleksandrovna Semenova, Marina Vasil'evna Vakhrusheva, Tamara Ivanovna Kolosheynova, Evgeniy Mikhaylovich Abakumov, Ekaterina Yur'evna Chelysheva, Svetlana Rudol'fovna Goryacheva, Tat'yana Vladimirovna Ivanova, Elena Stanislavovna Zakharova, Lyubov' Yur'evna Kolosova, Adel' Vladimirovna Zakharova, Irina Nikolaevna Naumova, Larisa Vladimirovna Dyachenko, Sergey Mikhaylovich Kulikov, Lidiya Grigor'evna Kovaleva, Nina Dmitrievna Khoroshko, A G Turkina, E V Domracheva, A V Vorontsova, E A Aseeva, O Yu Vinogradova, O V Stakhina, G A Gusarova, O A Dyagileva, E A Semenova, M V Vakhrusheva, T I Kolosheinova, E M Abakumov, E Yu Chelysheva, S R Goryacheva, T V Ivanova, E S Zakharova, L Yu Kolosova, A V Zakharova, I N Naumova, L V Dyachenko, S M Kulikov, L G Kovaleva, N D Khoroshko
Publikováno v:
Терапевтический архив, Vol 81, Iss 7, Pp 29-36 (2009)
Aim. To analyse clinical implications of chromosome 8 trisomy in Ph-negative cells of the bone marrow in patients with chronic myeloid leukemia (CML) treated with inhibitors of tyrosinkinases (ITK). Material and methods. A total of 386 patients with
Externí odkaz:
https://doaj.org/article/ede8cfd0b762457a94075ebaf7be705f
Autor:
Ol'ga Yur'evna Vinogradova, Anna Grigor'evna Turkina, Aleksandra Valer'evna Vorontsova, Ekaterina Yur'evna Chelysheva, Galina Anatol'evna Gusarova, S V Kuznetsov, Svetlana Rudol'fovna Goryacheva, Manana Aleksandrovna Sokolova, Evgeniy Mikhaylovich Abakumov, Ol'ga Veniaminovna Stakhina, Elena Vasil'evna Domracheva, Andrey Vital'evich Misyurin, Nina Dmitrievna Khoroshko, O Yu Vinogradova, A G Turkina, A V Vorontsova, E Yu Chelysheva, G A Gusarova, S R Goryacheva, M A Sokolova, E M Abakumov, O V Stakhina, E V Domracheva, A V Misyurin, N D Khoroshko
Publikováno v:
Терапевтический архив, Vol 81, Iss 7, Pp 41-46 (2009)
Aim. To analyse resistance to imatinib therapy, efficacy and safety of dasatinib. Material and methods. A total of 18 patients with chronic myeloid leukemia (CML) in a chronic stage received dasatinib for 9-30 months (median 30 months) to September 2
Externí odkaz:
https://doaj.org/article/52408b4dd35a4033bdaadedff47754a6